
A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
In this set of interviews, 6 leaders in the field of dermatology highlight their experiences at the 2025 EADV Congress.
At the






